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ABSTRACT
Background
Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disorder
characterized by progressive motor and cognitive dysfunction. Caused by an expanded
polyglutamine tract in ataxin 1 (ATXN1), SCA1 pathogenesis involves a multifactorial process
that likely begins with misfolding of ATXN1, which has functional consequences on its
interactions, leading to transcriptional dysregulation. Because lithium has been shown to exert
neuroprotective effects in a variety of conditions, possibly by affecting gene expression, we
tested the efficacy of lithium treatment in a knock-in mouse model of SCA1 (Sca1
154Q/2Q mice)
that replicates many features of the human disease.
Methods and Findings
Sca1
154Q/2Q mice and their wild-type littermates were fed either regular chow or chow that
contained 0.2% lithium carbonate. Dietary lithium carbonate supplementation resulted in
improvement of motor coordination, learning, and memory in Sca1
154Q/2Q mice. Importantly,
motor improvement was seen when treatment was initiated both presymptomatically and after
symptom onset. Neuropathologically, lithium treatment attenuated the reduction of dendritic
branching in mutant hippocampal pyramidal neurons. We also report that lithium treatment
restored the levels of isoprenylcysteine carboxyl methyltransferase (Icmt; alternatively, Pccmt),
down-regulation of which is an early marker of mutant ATXN1 toxicity.
Conclusions
The effect of lithium on a marker altered early in the course of SCA1 pathogenesis, coupled
with its positive effect on multiple behavioral measures and hippocampal neuropathology in
an authentic disease model, make it an excellent candidate treatment for human SCA1 patients.
The Editors’ Summary of this article follows the references.
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Spinocerebellar ataxia type 1 (SCA1) is one of nine known
dominantly inherited neurodegenerative disorders caused by
the expansion of a CAG repeat that encodes polyglutamine in
the respective disease protein [1]. Patients with SCA1 suffer
from progressive loss of motor coordination and some
cognitive deﬁcits. Pathologically, SCA1 is characterized by
degeneration of Purkinje cells and brain stem neurons, but
eventually generalized atrophy sets in [2–4].
There is strong evidence that expanded polyglutamine
tracts cause the host protein to misfold [5], but polyglutamine
pathogenesis is a complex, multifactorial process. In SCA1,
the nuclear localization of the mutant protein [6], protein
context, and protein modiﬁcation are all factors in disease
expression [7,8]. Emamian et al. [7] demonstrated that serine
776 (S776) in ataxin 1 (ATXN1) is essential for its pathoge-
nicity in transgenic mice; Chen et al. [8] showed that
phosphorylation of this residue by Akt enables 14-3-3 to
interact with and stabilize ATXN1. Genetic studies revealed
that overexpression of Hsp70 suppresses ATXN1-induced
degeneration, possibly through its effect on the misfolded
protein [9]. We sought to determine whether we could
improve the neurological dysfunction of SCA1 mutant mice
by using pharmacologic therapy that targets one of the
potential early downstream consequences of misfolded
ATXN1. An early event in the pathogenic cascade is the
down-regulation of the mRNAs of several genes. Lin et al.
demonstrated dysregulation of several neuronal genes in the
Purkinje cells of SCA1 transgenic mice even before the onset
of behavioral or neuropathological changes, and they ob-
served similar changes in the tissue of humans with SCA1 [10].
Therefore, we rationalized that if we use a drug that enhances
gene expression, we might slow SCA1 progression. Lithium
was recently shown to exert neuroprotective effects, possibly
by affecting gene transcription [11,12]. Lithium is widely
known for its use in the treatment of bipolar disease. The
mechanism of lithium’s mood-stabilizing activity has not been
elucidated, in part because lithium exerts its effects on a wide
range of cellular functions: for example, it inhibits inositol
production, affects the protein kinase C signaling pathway,
and inhibits glycogen synthase kinase 3 (GSK3) [13–15].
Furthermore, several studies in cellular and animal models
have shown that lithium can suppress neurodegeneration
induced by various kinds of insults, such as Alzheimer disease
amyloid-b peptide [16], glutamate [17], and ischemia [17].
Carmichael et al. reported that lithium treatment partially
rescued cell death in cells overexpressing Huntington disease
exon 1 fragment with 74 glutamines, possibly by inhibiting
GSK3 and subsequently altering gene transcription [11].
The Sca1
154Q/2Q knock-in mouse model bears 154 CAG
repeats in the mouse Sca1 locus and expresses full-length
mutant ATXN1 in its endogenous expression pattern and
context [18]. Sca1
154Q/2Q mice reproduce many features of the
human disease, including progressive motor dysfunction and
cognitive impairment [18], and therefore allow us to examine
a range of effects of lithium treatment on SCA1 pathogenesis
in vivo.
Methods
Mice and Treatment Regimen
Sca1
154Q/2Q mice and their wild-type littermates were
obtained from crossings between male Sca1
154Q/2Q mice and
wild-type female mice on two different backgrounds: mice of
C57BL/6J–129/SvEv mixed background; and mice that were
obtained after C57BL/6J–129/SvEv mutant mice were back-
crossed to C57BL/6J at least ﬁve times (.N5 generation). They
were randomly assigned to two groups either at the time of
weaning (presymptomatic) or at ﬁve weeks (symptomatic), at
which time treatment was initiated. Each group was fed either
0.2% lithium carbonate-containing chow or control Purina
rodent chow (Harlan Teklad, http://www.teklad.com). All
behavioral tests were conducted by individuals blind to
genotype and treatment group. Animals were separated by
treatment and three to ﬁve animals were housed per cage.
Mouse experiments followed protocols approved by the
Baylor College of Medicine Institutional Animal Care and
Use Committee (IAUAC) and the Institutional Animal Care
and Use Committee of Tokyo Medical and Dental University.
Determination of Serum Lithium Levels
The LI Flex reagent cartridge (Dade Behring, http://www.
dadebehring.com) was used on the Dimension clinical
chemistry system as an in vitro test to quantitatively measure
lithium levels in rodent serum. The LI method of measure-
ment employs a patented compound (lithium dye) that reacts
with lithium ions in an alkaline mixture of water and DMSO
to form a noncovalent binary complex, the absorbance of
which is measured at 540 nm and is directly proportional to
lithium concentration in the sample. The LI method of
measurement was carried out by the standard operating
procedures of the Department of Pathology, Harris County
Hospital District, Houston, Texas, United States.
Rotarod Test
An accelerated rotating rod test (type 7650; Ugo Basile,
http://www.ugobasile.com) allowed us to evaluate coordina-
tion and motor skill acquisition. Naı ¨ve animals at 10 and 13
wk of age were placed on the rod (diameter 3 cm, length 30
cm) in four trials every day for a period of 4 d. Each trial
lasted a maximum of 10 min, during which time the rotating
rod underwent a linear acceleration from 4 to 40 rpm over
the ﬁrst 5 min of the trial and then remained at maximum
speed for the remaining 5 min. The time mice spent on the
rod without falling was recorded.
Morris Maze
Mice aged 9–11 wk were trained in the Morris water maze
to locate a hidden platform as described elsewhere [18]. Each
mouse was given four trials per day for ﬁve consecutive days.
After trial 20, each animal was given a probe trial. During the
probe trial, the platform was removed and each animal was
allowed to search the pool for 60 s.
Pavlovian Conditioned Fear
Mice were 11–13 weeks of age at the start of testing.
Performance in a conditioned fear paradigm was measured as
described before [14] using a Freeze Monitor system (San
Diego Instruments, http://sandiegoinstruments.com). The test
chamber was made of clear Plexiglas and surrounded by a
photo beam detection system. The ﬂoor of the test chamber
was a grid used to deliver an electric shock. A mouse was
placed in a test chamber and allowed to explore freely for 2
min. An 80 dB white noise that served as the conditioned
stimulus (CS) was then presented for 30 sec, and then
followed by a mild foot shock (the unconditioned stimulus,
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sented. The mouse was removed from the chamber 15–30 s
later and returned to its home cage. After 24 h, the mouse was
placed back into the test chamber for 5 min and ‘‘freezing’’
behavior was assessed for 5 min (context test). Environmental
and contextual cues were changed for the auditory CS test: a
white Plexiglas triangular insert was placed in a chamber to
alter its shape and spatial cues, the wire grid ﬂoor was
covered with white Plexiglas, and vanilla extract was placed in
the chamber to alter the smell. There were two phases during
the auditory CS test. In the ﬁrst phase (pre-CS), freezing was
recorded for 3 min without the CS. In the second phase, the
auditory CS was presented, and freezing was recorded for
another 3 min. The time mice froze was converted to a
percentage freezing value. For the auditory CS test, the
percentage freezing value obtained during the pre-CS period
was subtracted from the percentage freezing value when the
auditory CS was present.
Open-Field Test
At 2 wk after the conditioned fear test, the Sca1
154Q/2Q mice
were placed in the center of an open-ﬁeld space (40340330
cm). Activity was quantiﬁed by a computer-operated Digiscan
optical animal activity system (RXYZCM, Acuscan, http://
acuscan.com). Each test session was 30 min long, and data
were collected in 10 min intervals.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry and immunoﬂuorescence staining
were performed as described elsewhere [18]. Rabbit poly-
clonal anti-ataxin-1 (11NQ) and monoclonal anti-calbindin
antibodies (Sigma, http://www.sigmaaldrich.com) were used
for the staining of neuronal intranuclear inclusions (NI) and
the dendritic arbors of Purkinje cells, respectively. The
quantiﬁcation of the dendritic arborization was carried out
using the NIH Image J software as previously described [18].
Golgi Staining and Sholl Analysis
Sca1
154Q/2Q mice and their wild-type littermate pairs,
between the ages of 24 and 30 weeks, fed on either control
or lithium diet from the time of weaning, were used for these
experiments (three to six mice per treatment group).
Individuals performing experimental manipulations and
subsequent analyses were blind to both genotype and treat-
ment group. Golgi staining was carried out using the FD
NeuroTechnologies Rapid Golgi Staining Kit according to the
manufacturer’s protocol (FD NeuroTechnologies, http://www.
fdneurotech.com). Sagittal brain sections (60 lm) were
prepared and camera lucida drawings were used to trace
the morphology of hippocampal CA3 pyramidal neurons.
Representative pyramidal cells were drawn at a magniﬁcation
of 4003. Tracings of 6–10 neurons were made per animal, for
a total of 30–60 neurons per treatment group. Sholl analysis
of the apical and basilar dendrites of these neurons was then
carried out. Brieﬂy, a series of increasingly large concentric
circles centered at the cell body and separated by 20 mm
intervals were superimposed upon traces of apical and basilar
dendrites; the number of dendritic intersections with each
concentric circle was recorded.
Immunoblotting
Brain extracts were prepared with ice-cold lysis buffer (0.25
M Tris [pH 7.5]) containing protease inhibitors (Protease
Inhibitor Cocktail tablets, Roche Diagnostics, http://www.
roche.com/div_diag.htm) and phosphatase inhibitors (Phos-
phatase Inhibitor Cocktails I & II, Sigma). Proteins were
separated in 10% SDS-polyacrylamide gels and transferred
onto nitrocellulose membranes. Blots were probed with
antibodies to Akt (Cell Signaling, http://www.cellsignal.com),
phospho-serine473-Akt (Cell Signaling), phospho-threo-
nine308-Akt (Cell Signaling), and phospho-serine9-GSK3b
(Cell Signaling) as well as those to GAPDH (Advanced
ImmunoChemical, http://www.advimmuno.com) which was
used as a loading control.
Statistical Analysis
The Rotarod behavioral scores were subjected to statistical
analysis using one-way or two-way ANOVA with repeated
measures. For the Morris maze, escape latency was analyzed
using two-way ANOVA with repeated measures. Probe trial
was analyzed by one-way ANOVA followed by Student-
Newman-Keuls post-hoc test to detect signiﬁcant learning
in each experimental group. One-way ANOVA was then
performed to compare the search time for the training
quadrant and multiple comparisons among all the groups
were performed using Scheffe post hoc test. In the Pavlovian
conditioned fear test, the percentage freezing was deter-
mined as described above, with a two-tailed t-test used to
analyze the effects of treatment on percentage freezing. Sholl
analysis data were analyzed using a multivariate analysis of
variance (MANOVA). The MANOVA models considered both
the effects of genotype and lithium treatment as well as the
genotype and lithium treatment interaction effect. For a
more direct analysis of the effect of lithium treatment,
multivariate comparison of group means (control wild-type
[Cont WT] versus lithium-treated wild-type [Li WT]; control
knock-in [Cont KI] versus Cont WT; and Cont KI versus
lithium-treated knock-in [Li KI]) was also performed using
Hotelling T-statistic, utilizing the MANOVA ﬁt to estimate
the covariance. We performed t-tests (not assuming equal
variances) and one-way repeated measures ANOVA using the
StatView software (http://www.statview.com); R software
(http://www.r-project.org) was utilized to perform the MAN-
OVA. The other statistical analyses, including two-way
repeated measures ANOVA, were performed with the SPSS
statistical software package (http://www.spss.com).
Results
Effects of Lithium Carbonate Treatment on Motor
Coordination in Sca1
154Q/2Q Mice
At three weeks of age, upon weaning from their mothers,
Sca1
154Q/2Q mice and their wild-type littermates were main-
tained on regular rodent chow or on a diet containing 0.2%
lithium carbonate. This treatment gave a plasma concen-
tration above the minimal therapeutic concentration (0.6
mM) for treatment of bipolar disorder in both wild-type (0.83
mM, n¼1, at 15 wk; 0.87 mM, n ¼1, at 24 wk) and Sca1
154Q/2Q
mice (0.91 6 0.04 mM, n ¼ 12, at 15 wk). Wild-type and
Sca1
154Q/2Q mice receiving lithium carbonate appeared to
consume more water (possibly due to lithium’s diuretic
action) and gained less weight between three and six weeks
of age than did wild-type and mutant mice on a control diet,
respectively. After seven weeks of age, however, both treated
groups gained more weight than their respective untreated
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groups became similar at ten weeks of age (Figure 1A).
In order to examine the effect of lithium treatment on
motor coordination, we tested Sca1
154Q/2Q mice of C57BL/6J-
129/SvEv mixed background on the accelerating rotating rod.
Because body weight signiﬁcantly affects the performance of
mice on the rotating rod, we performed this behavioral assay
after ten weeks of age when the weights of lithium-treated
mutant and control animals were comparable to their
respective untreated counterparts. Two-way repeated meas-
ures ANOVA performed on the data set containing lithium-
treated and untreated mutant animals revealed that there was
a signiﬁcant treatment effect (p ¼ 0.0376), mediated by the
enhanced performance of the lithium-treated mutant animals
compared to mutant animals reared on a control diet at ten
weeks of age (Figure 1B). In contrast, lithium did not produce
a signiﬁcant improvement in the performance of wild-type
mice in comparison to wild-type mice on a control diet (p ¼
0.198, Figure 1B). To see if these ﬁndings were reproducible,
we tested another batch of lithium-treated mutant animals
whose genetic background was closer to C57BL/6J after ﬁve
backcrosses (N5 generation). These animals showed signiﬁ-
cantly better performance on the accelerating Rotarod at 13
weeks of age than untreated age- and weight-matched mutant
animals (p ¼ 0.0192, by repeated measures ANOVA, Figure
1C). These ﬁndings were reproduced in a second cohort of
Figure 1. Lithium Treatment Improves Motor Coordination in Sca1
154Q/2Q Mice
(A) Body weights of Sca1
154Q/2Q mice on a diet with (Li KI) or without (Cont KI) 0.2% lithium carbonate supplementation. *p , 0.02 by Student t-test.
(B–D) Rotarod analysis. Ten-week-old naı ¨ve mice (B and D) and 13 week-old naı ¨ve Sca1
154Q/2Q (C) mice were trained on the accelerating Rotarod in four
trials per day (T1–T4) for 4 d (D1–D4). Lithium treatment was started either at the time of weaning (B and C) or at five weeks of age (D), when the
Sca1
154Q/2Q mice already show motor impairments. In both (B) and (D), repeated measures ANOVA revealed a significant time by day interaction for
each of the four groups (unpublished data). Two-way repeated measures ANOVA indicated there were main effects of genotype (p , 0.001 for [B]; p¼
0.002 for [D]) and treatment (p¼0.037 for [B] and p¼0.005 for [D]), but their interaction was not significant in (B) (p¼0.491) or (D) (p¼0.115). Cont KI,
Sca1
154Q/2Q mice on control diet; Li KI, lithium-treated Sca1
154Q/2Q mice on lithium-supplemented diet; Li WT, wild-type mice on lithium-supplemented
diet; Cont WT, wild-type mice on control diet. All data are shown as mean 6 SEM.
doi:10.1371/journal.pmed.0040182.g001
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data). These data suggest that continued lithium treatment
improved motor coordination in the Sca1
154Q/2Q mice
regardless of the genetic background of the animals.
Sca1
154Q/2Q mice developed motor incoordination as early
as ﬁve weeks of age [18]. In order to examine if lithium is
effective after onset of symptoms, we evaluated the perform-
ance of backcrossed (N8 or above) mutant animals that were
given the lithium-containing chow after 5 weeks of age. These
animals also showed signiﬁcantly improved performance on
the Rotarod at ten weeks of age compared to untreated age-
and weight-matched mutant animals (p ¼ 0.0358, by repeated
measures ANOVA, Figure 1D). These results suggest that the
lithium treatment is effective even when it is initiated
postsymptomatically. More importantly, the reproducibility
of the effects of lithium on four independent cohorts of
Sca1
154Q/2Q mice speaks to the positive effect of this drug on
the coordination phenotype.
The Performance of Lithium-Treated Sca1
154Q/2Q Mice in
Learning and Memory Tasks
We next studied the effects of lithium treatment on
cognitive function in 9- to 13-week-old Sca1
154Q/2Q mice
(Figure 2). We have previously shown that both spatial and
Pavlovian learning and memory are impaired in Sca1
154Q/2Q
mice, as reﬂected by their performance on the Morris water
maze and conditioned fear tests, respectively [18]. In the
hidden platform version of the Morris water maze, nine- to
11-week-old lithium-treated Sca1
154Q/2Q mice located the
platform in signiﬁcantly less time than those on a control
diet (p , 0.0001, by repeated measures ANOVA, Figure 2A).
During the probe trial on day 5, lithium-treated Sca1
154Q/2Q
mice spent more time in the training quadrant than the
untreated mutants (Figure 2B). This difference was probably
not attributable to increased motor activity, because lithium-
treated Sca1
154Q/2Q mice and untreated mutants displayed
similar swim speeds during the probe trial (treated, 17.5 6 0.8
cm/s; untreated, 16.2 6 0.9 cm/s, mean 6 SEM; n ¼ 10 and 7
animals, respectively). The performance of wild-type mice
was not signiﬁcantly affected by lithium treatment. These
results suggest that the lithium treatment improved spatial
learning selectively in the Sca1
154Q/2Q mice.
Two types of fear-conditioning paradigms, contextual and
cued fear conditioning tests, were used to assay Pavlovian
learning and memory in the lithium-treated Sca1
154Q/2Q mice.
These paradigms are thought to depend on plastic changes in
the basolateral nucleus of the amygdala, with contextual fear
conditioning also involving the hippocampus [19–21]. For the
present study, the mice were placed in a chamber and twice
given a mild foot shock paired with white noise. Twenty-four
hours after this training, the mice were placed in the same
chamber and their freezing behavior was monitored, in
response to either the context (contextual fear conditioning)
or the acoustic stimulus (white noise) delivered in a different
context (cued fear conditioning). The degree of freezing
indicates how well the animals remember the context or the
cue. Sca1
154Q/2Q mice on a control diet exhibited signiﬁcant
deﬁcits in fear conditioning (low levels of freezing) in both
the cued and contextual tests compared to wild-type mice
(Figure 2C and 2D). Lithium-treated Sca1
154Q/2Q mice showed
signiﬁcantly greater levels of freezing than the untreated
mutant animals in the contextual test, whereas wild-type
controls behaved similarly on the task independent of lithium
treatment (Figure 2C). Lithium-treated and untreated
Sca1
154Q/2Q mice performed similarly in the cued test, but it
is interesting that lithium-treated wild-type mice displayed
increased freezing in the cued test (Figure 2D). The selective
effect of the lithium treatment on the performance of
Sca1
154Q/2Q mice is not likely to be attributable to their
decreased activity or the nonspeciﬁc sedative effects of the
treatment, for two reasons. First, both lithium-treated and
untreated wild-type mice showed similar levels of freezing in
the context test. Second, both lithium-treated and untreated
mutant animals showed similar levels of activity when they
were tested in the open-ﬁeld test (Figure 2E). Overall, these
data indicate that lithium treatment selectively improved
learning and memory measures in Sca1
154Q/2Q mice. Speciﬁ-
cally, the combined data from the Morris water maze and
contextual fear conditioning support a positive effect of
lithium on the hippocampus-dependent memory of Sca1
154Q/
2Q mice.
Neuropathology of Lithium-Treated Sca1
154Q/2Q Mice
Examination of hematoxylin-eosin-stained brain sections
revealed no differences in gross morphology between
lithium-treated and untreated Sca1
154Q/2Q mice at 17–36
weeks of age. We additionally compared NI formation in
the mutant brains, given that previous immunohistochemical
studies with anti-ATXN1 antibodies demonstrated that
Sca1
154Q/2Q mice develop extensive NI formation in hippo-
campal neurons but delayed and less abundant NI formation
in mutant Purkinje neurons [18]. In 30- to 36-week-old
lithium-treated Sca1
154Q/2Q mice, we found no signiﬁcant
difference in the percentage of hippocampal or Purkinje
neurons harboring ATXN1-positive NI compared to litter-
mate Sca1
154Q/2Q mice on a control diet (by t-test, Figure 3),
suggesting that the chronic lithium treatment did not
signiﬁcantly affect the magnitude or distribution of NI
formation in the Sca1
154Q/2Q mice.
To determine if lithium therapy has an effect on the
neurodegenerative changes associated with SCA1 patho-
genesis, we ﬁrst analyzed dendritic arborization of the mutant
Purkinje neurons quantitatively using anti-calbindin immu-
noﬂuorescence [18]. Reduced dendritic arborization of
Purkinje neurons was noted as early as nine weeks of age in
the Sca1
154Q/2Q mice [18]. Both lithium-treated and control
mutant animals displayed similar intensities of calbindin
immunoﬂuorescence throughout the Purkinje cell layer and
molecular layer of the cerebellum at 17 weeks of age,
indicating that lithium treatment did not signiﬁcantly affect
dendritic degeneration of Purkinje cells in Sca1
154Q/2Q mice
(unpublished data).
Sca1
154Q/2Q mice not only suffer from deﬁcits in hippo-
campus-dependent learning and memory, but also show
hippocampal atrophy in the absence of apparent cell loss
[18]. In order to examine the dendritic morphology of the
mutant hippocampal pyramidal neurons and determine
whether differences in performance on hippocampus-de-
pendent tasks correlated with improvements in cellular
pathology, we examined dendritic arborization of CA3
pyramidal neurons by Sholl analysis of Golgi preparations
[22]. Inspection of camera lucida drawings of pyramidal
neurons from Sca1
154Q/2Q or wild-type mice on control or
lithium diet revealed differences in dendritic arborization
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MANOVA indicated that there were signiﬁcant genotype and
lithium treatment effects as well as signiﬁcant interaction
between genotype and lithium treatment for basilar, and to a
lesser extent, apical dendrites (interaction effect: p , 0.001,
basilar; p ¼ 0.053, apical [Figure 4E and 4F]). Speciﬁcally, by
multivariate contrast analysis, Sca1
154Q/2Q mice had signiﬁ-
cantly fewer branch intersections than wild-type mice, and
lithium treatment signiﬁcantly improved this measure (Cont
KI versus Cont WT: p , 0.001, basilar and apical; Cont KI
versus Li KI, p¼0.007, basilar; p¼0.031, apical, Figure 4E and
4F). These results suggest that chronic lithium treatment,
which was started from the time of weaning, partially rescued
the degenerative changes seen in the hippocampal CA3
neurons of Sca1
154Q/2Q mice. It is of note that although
chronic lithium therapy decreased dendritic branching in
Figure 2. Sca1
154Q/2Q Mice Reared on Lithium-Containing Chow Have Improved Learning and Memory Functions
(A and B) Performance of nine- to 11-week old mice on the Morris hidden-platform water maze. Sca1
154Q/2Q mice on the control diet (Cont KI) learned
more slowly than those given lithium (Li KI). In a 60 s probe trial (B), Cont KI spent significantly less time in the training quadrant than Li KI (p¼0.012 by
multiple comparisons using Scheffe’s post hoc test), whereas Li KI spent similar amounts of time in the training quadrant compared to wild-type mice
given lithium (Li WT) (p ¼ 0.770) or wild-type mice on the control diet (Cont WT) (p ¼ 0.847).
(C and D) Pavlovian conditioned fear for Sca1
154Q/2Q (KI) and wild-type (WT) mice treated with lithium (Li) or fed control chow (Cont). Percentage of
time spent in freezing behavior during the contextual test (C) and the cued test (D) is shown.
(E) Open-field activity for Sca1
154Q/2Q mice. Locomotor activity of lithium-treated and untreated mutant mice was measured two weeks after the
conditioned fear test. Each panel indicates total distance traveled (left graph) and time spent moving (right graph). All data are shown as mean 6 SEM.
doi:10.1371/journal.pmed.0040182.g002
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p ¼ 0.024, apical [Figure 4E and 4F]), it proved protective in
the context of the SCA1 mutation.
Levels of Icmt/Pccmt mRNA in Lithium-Treated Sca1
154Q/2Q
Mice
Altered expression of speciﬁc genes has been implicated in
the pathogenesis of several polyglutamine diseases [1,10]. In
the case of SCA1, down-regulation of the isoprenylcysteine
carboxyl methyltransferase (Icmt; alternatively, Pccmt) gene in
Purkinje cells is one of the earliest known molecular
alterations occurring in SCA1 transgenic mice [10]. In order
to conﬁrm that alterations in expression of Icmt/Pccmt occur
in the Sca1
154Q/2Q mice as well, we examined Icmt/Pccmt mRNA
expression in the cerebellum of Sca1
154Q/2Q and wild-type
mice by Northern analysis (Figure 5). In Sca1
154Q/2Q cerebel-
lum, the expression of Icmt/Pccmt mRNA was down-regulated
as early as ten weeks of age and markedly decreased by 16
weeks of age (Figure 5A and 5B). Because Icmt/Pccmt down-
regulation is one of the earliest known alterations in both
SCA1 transgenic mice and Sca1
154Q/2Q mice, and because this
gene is also down-regulated in human postmortem samples,
we consider it a reliable early marker of transcriptional
dysregulation and disease pathogenesis. Lithium treatment of
the Sca1
154Q/2Q mice resulted in almost normal levels of Icmt/
Pccmt mRNA at ten weeks of age (Figure 5B). Densitometric
analysis of the blots from four independent experiments
revealed Icmt/Pccmt expression to be signiﬁcantly elevated in
lithium-treated knock-in mice (10–28 weeks of age) in
comparison with the untreated knock-in littermates (p ¼
0.024 by t-test, Figure 5B, right column). In fact, the levels of
Icmt/Pccmt mRNA in treated mutant animals were close to
normal (98% of untreated wild-type animals), based on
analysis of four independent pairs (ten Sca1
154Q/2Q and 12
wild-type mice, total). Thus,c h r o n i cl i t h i u mt r e a t m e n t
resulted in restoration of the levels of one of the earliest
molecular changes in Sca1
154Q/2Q mice—cerebellar transcrip-
tional dysregulation of Icmt/Pccmt almost to normal.
Effects of Lithium on GSK3b Phosphorylation and Akt
Phosphorylation in Sca1
154Q/2Q Mouse Brains
The above results suggest that one of the ways lithium
treatment ameliorated the behavioral deﬁcits and hippo-
campal neuropathology of Sca1
154Q/2Q mice might be by
affecting neuronal gene expression. There are two major
pathways by which lithium is known to affect the activities of
multiple transcription factors that control gene expression,
and both of these pathways involve inhibitory effects on
GSK3: lithium can act as a competitive inhibitor of Mg
2þ,
thereby reducing GSK3 activity [14]; lithium also inhibits
GSK3 by increasing the inhibitory phosphorylation of a Ser-9
residue in GSK3b or Ser-21 on GSK3a [14]. Chronic
administration of lithium to mice has been shown to cause
an increase in the phosphorylation of Ser-9 of GSK3b in vivo.
We therefore examined the effects of lithium treatment on
the phosphorylation of Ser-9 of GSK3b using hippocampal
extracts from nine-week-old animals. Phospho-Ser-9-GSK3b
levels were indeed greater in the hippocampi of lithium-
treated mice (both wild-type and Sca1
154Q/2Q) than in their
untreated littermates (Figure 6A). Similar results were
obtained from cerebellar extracts of these animals (Figure
6A).
The mechanism by which lithium enhances phospho-Ser-9-
GSK3b levels has not been fully resolved. GSK3b is known to
be a substrate of serine/threonine kinase Akt, and Akt is
mostly regulated through the phosphoinositol-dependent
phosphorylation of both its Ser-473 and Thr-308 residues,
resulting in its activation. It has been reported that lithium
might increase phosphorylation of either of the two residues
through activation of phosphatidylinositol 3-kinase [24,25].
Other reports have postulated that GSK3b phosphorylation is
increased through inhibition of a protein phosphatase that
normally removes a phosphate from the regulatory serine
[26]. To determine which of these two scenarios might
account for enhanced levels of phospho-Ser-9-GSK3b,w e
examined phosphorylation of Akt on Ser-473 and Thr-308.
We did not ﬁnd enhanced levels of phospho-Ser-473-Akt
(Figure 6A) nor phospho-Thr-308-Akt (Figure 6B) in the
brains of lithium-treated mice (either Sca1
154Q/2Q or wild-
type).
Discussion
We have shown that lithium carbonate mitigates the severe
motor dysfunction and cognitive impairment observed in
Sca1
154Q/2Q mice. Motor dysfunction improved even when
treatment was initiated after the onset of symptoms. Sholl
analysis revealed dendritic pathology in hippocampal CA3
pyramidal neurons of Sca1
154Q/2Q mice, which was partially
rescued upon lithium treatment. In addition, we have shown
that the expression of the Icmt/Pccmt gene, whose down-
regulation is an early marker of SCA1 pathology, is elevated
after lithium treatment in Sca1
154Q/2Q mice. The ﬁnding of
increased phospho-GSK3b supports the hypothesis that these
effects could be mediated at least in part through tran-
scription.
Figure 3. Lithium Treatment Does Not Affect NI Formation in Sca1
154Q/2Q
Mice
The percentage of NI-harboring neurons is shown for 30- to 36-week-old
mutant mice. Numbers of animals used for counting hippocampal
neurons were six for lithium-treated Sca1
154Q/2Q mice (Li KI) and four for
Sca1
154Q/2Q mice on the control diet (Cont KI); numbers of animals used
for counting Purkinje cells were three for Li KI and three for Cont KI. Error
bars indicate SEM.
doi:10.1371/journal.pmed.0040182.g003
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Lithium Benefits SCA1 Mouse ModelFigure 4. Lithium Treatment Partially Rescues Dendritic Pathology in Hippocampal CA3 Pyramidal Neurons of Sca1
154Q/2Q Mice
(A–D) Camera lucida drawings of representative pyramidal cell neurons from each experimental group. Shown are wild-type, control diet (Cont WT; n¼
5 mice, 50 neurons) (A); wild-type, lithium diet (Li WT; n¼3 mice, 30 neurons) (B); Sca1
154Q/2Q knock-in, control diet (Cont KI; n¼3, 30 neurons) (C); and
(D) Sca1
154Q/2Q knock-in, lithium diet (Li KI; n ¼ 6, 60 neurons).
(E and F) The effects of lithium treatment on the branching pattern of basilar (E) and apical (F) dendrites at increasing distances from the soma are
shown. Genotype and lithium treatment significantly altered both basilar (E) and apical dendritic intersections (F) (genotype effect: p , 0.001, for basilar
and apical; lithium treatment effect: p ¼ 0.025 for basilar, p ¼ 0.018 for apical). Sholl analysis additionally indicated a significant interaction between
lithium treatment and genotype (p , 0.001 for basilar, p ¼ 0.053 for apical). Values represent mean 6 SEM.
doi:10.1371/journal.pmed.0040182.g004
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Lithium Benefits SCA1 Mouse ModelLithium has been reported to exert its neuroprotective
effects predominantly by inhibiting apoptosis through
inhibition of GSK3b [27]. Given the lack of evidence linking
apoptosis with the pathogenesis of SCA1 [18,28,29], we think
it is unlikely that the beneﬁcial effects of lithium on
neurological function arose from such antiapoptotic activ-
ities in Sca1
154Q/2Q mice. There are, however, several other
possible modes of activity by which lithium may improve the
course of the disease in Sca1
154Q/2Q mice. Lithium has diverse
molecular targets (including GSK3b) that affect gene ex-
pression, and chronic lithium treatment has been reported to
increase the DNA binding activity of the transcription factor
AP-1 in rat brains [30]. Since alteration in gene expression is
an early step in SCA1 pathogenesis, it is conceivable that
lithium could exert some of its neuroprotective effect by
favorably affecting gene expression in the mutant mice.
Although it is unclear whether the enhanced levels of Icmt/
Pccmt mRNA contributed to the improved behavioral proﬁle
of treated Sca1
154Q/2Q mice, the normalization of its levels
suggest that lithium might help also correct some of the
transcriptional dysregulation underlying SCA1.
Our Sholl analysis data suggest that the lithium treatment
could improve cognitive dysfunction in Sca1
154Q/2Q mice,
p o s s i b l yb yp a r t i a l l yr e s c u i n gd e n d r i t i ca t r o p h yo ft h e
mutants’ hippocampal pyramidal neurons. It is interesting
that chronic lithium treatment has been reported to prevent
the stress-induced decrease in dendritic length in CA3
hippocampal neurons [31]. Thus, it is plausible that the
Figure 5. Lithium Treatment Increases Icmt/Pccmt mRNA Levels in
Sca1
154Q/2Q Cerebellum
(A) Temporal profile of Icmt/Pccmt mRNA down-regulation in the
Sca1
154Q/2Q cerebellum. Cerebellar expression levels of Icmt/Pccmt mRNA
in Sca1
154Q/2Q mice and wild-type littermates were compared by
Northern analysis. Ethidium bromide-stained RNA gel images are shown
as a loading control, which was confirmed by hybridization with Gapdh.
25 lg of total RNA obtained from one cerebellum was loaded in each
lane. Densitometric analysis using Gapdh as a control revealed a relative
abundance of 0.465 for the 25 week-old Sca1
154Q/2Q cerebellum
compared to the respective wild-type littermate cerebella.
(B) Northern blots of cerebellar RNA (25 lg) from two Sca1
154Q/2Q mice
and two wild-type littermates treated with lithium (þ) or control diet ( )
at ten weeks of age (blots on left) were probed with Icmt/Pccmt and
Gapdh cDNAs. Quantitative analysis from four independent experiments
(bar graph on right), in which total cerebellar RNAs were obtained from
one or two Sca1
154Q/2Q mice and one or two wild-type littermates for
each experimental group (in total, six Sca1
154Q/2Q mice on lithium diet,
four Sca1
154Q/2Q mice on control diet, six wild-type mice on lithium diet,
and six wild-type mice on control diet), indicates Icmt/Pccmt expression
was significantly increased in lithium-treated Sca1
154Q/2Q mice (bar graph
on right). Error bars indicate mean 6 SEM.
doi:10.1371/journal.pmed.0040182.g005
Figure 6. Phospho-Ser-9-GSK3b, but not Phospho-Akt, was Up-
Regulated in Lithium-Treated Mouse Brains
(A) Phospho-Ser-9-GSK3b, but not phospho-Ser-473-Akt, was up-
regulated in lithium-treated mouse brains. Shown are blots of hippo-
campal (left) and cerebellar (right) extracts from Sca1
154Q/2Q mice (KI) and
wild-type littermates (WT), with (þ) or without ( ) lithium treatment,
immunolabeled with phospho-Ser9-GSK3b, phospho-Ser473-Akt, and
GAPDH antibodies. Each number indicates relative intensity of the band
compared to the intensity of wild-type mice without the treatment.
(B) Phospho-Thr-308-Akt was not up-regulated in the lithium treated
mouse brains. Shown are blots of hippocampal (left) and cerebellar
(right) extracts from Sca1
154Q/2Q mice (KI) and wild-type littermates (WT),
with (þ) or without ( ) lithium treatment, immunolabeled with phospho-
Thr308-Akt, total Akt, and GAPDH antibodies. Similar results were
obtained from the extracts from the rest of the brains. Each number
indicates relative intensity of the band compared to the intensity of wild-
type mice without the treatment. On each immunoblot, individual lanes
were loaded with a protein extract prepared from one animal and similar
results were reproduced with one to three more independent experi-
ments (two to four animals in total were used).
doi:10.1371/journal.pmed.0040182.g006
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Lithium Benefits SCA1 Mouse Modelpathogenic mechanism of mutant ATXN1-induced dendritic
atrophy shares common downstream pathways with that of
stress-induced dendritic remodeling, which was shown to
depend on excitatory amino acid activity [32]. Lithium could
also affect neurotransmission or neurogenesis. Chronic
lithium treatment up-regulates synaptosomal uptake of
glutamate [33], and lithium treatment enhances long-term
potentiation in the rat dentate gyrus [34]. It has also been
reported that chronic administration of lithium enhances
neurogenesis in the dentate gyrus of adult rodents [35].
Our trials in a faithful mouse model of SCA1, which
expresses endogenous levels of mutant, full-length ATXN1
protein in a proper spatial and temporal pattern and
reproduces many features of the human disease, strongly
suggest that the therapeutic potential of lithium in this
disease deserves serious consideration. Importantly, the
lithium trial improved the motor impairment even when it
was started after the onset of disease in Sca1
154Q/2Q mice.
However, it remains unclear whether all the beneﬁcial effects
of lithium would last throughout the disease course. When we
tested the mice on the rotarod at 20 weeks of age, we found
signs of improved performance but the differences failed to
reach statistical signiﬁcance between the treated and un-
treated mutant mice (p ¼ 0.102, by repeated measures
ANOVA). Thus, lithium may not confer long-lasting beneﬁts.
Nonetheless, we cannot rule out whether using a less
challenging paradigm might be required to delineate differ-
ences in the motor performance at this stage. We did not
observe a signiﬁcant improvement in life span (unpublished
data), but life span measurement could also be confounded by
various factors. For instance, it has been shown that long-
term lithium treatment could disturb serum ionic balance in
rodents [36] such that effects on normal functions of organs
outside the central nervous system could have confounded
life span measures. Further, because the Sca1
154Q/2Q mice
express a CAG tract that is much longer than typically seen in
human patients (in order to produce a phenotype during the
short life span of the mouse [37]), their disease might be more
aggressive than the human condition. Finally, the therapeutic
and toxic potential of lithium have been well documented;
tremor and lack of coordination are among the side effects
reported, particularly when the dose is not carefully
monitored [38]. Because such side effects could be of concern
when treating patients with a disorder of cerebellar dysfunc-
tion, we evaluated tremor events in mice using a tremor
monitoring system. We did not ﬁnd any indication of
increased tremor in chronically lithium-treated Sca1
154Q/2Q
or wild-type mice (unpublished data), suggesting that the
lithium trial at the doses used in our study did not induce
tremors even in the context of an ATXN1 mutation.
It is interesting to note that lithium has produced
beneﬁcial effects in a cellular, Drosophila, and mouse model
of Huntington disease toxicity in which fragments of
polyglutamine expanded mutant huntingtin were expressed.
Lithium chloride treatment reduced toxicity induced by
overexpression of Huntington disease exon 1 fragment with
74 glutamines in neuronal and non-neuronal cell lines [11],
and attenuated toxicity of the N-terminal part of mutant
huntingtin with 120 glutamine repeats in Drosophila [39].
Wood and Morton recently showed that chronic lithium
treatment improved motor function in a transgenic mouse
model of Huntington disease (the R6/2 line) that expresses
exon 1 of the human huntingtin gene with approximately 150
CAG repeats [40]. In this study, lithium improved the
performance of the mice in one behavioral paradigm, the
rotating rod, but only in animals treated postsymptomatically
[40]. It remains to be seen if lithium therapy would be
beneﬁcial in mouse models of HD that express the full-length
protein. This experiment is critical because protein context
has increasingly been shown to be important in the patho-
genesis of polyglutamine disorders, such that normal function
of the full-length host protein may determine molecular
pathways, pathogenic progression, and potential therapeutic
targets [41,42]. Here, we show the beneﬁcial effects of chronic
lithium treatment on multiple measures in an SCA1 disease
model—Sca1
154Q/2Q mice—that express the full-length mutant
protein in the endogenous spatiotemporal pattern and
reproduce most features of human SCA1. Future studies
using other polyglutamine diseases, particularly the knock-in
mouse models, will be necessary to determine whether
lithium will prove effective for polyglutamine diseases in
general or will have a more limited therapeutic role.
Lithium’s amelioration of the phenotypes of Sca1
154Q/2Q
mice may occur through more than one mechanism.
Consistent with this idea is the ﬁnding that several inde-
pendent neurological functions are improved in lithium-
treated Sca1
154Q/2Q mice along with an apparent differential
morphological effect on Purkinje cells and hippocampal
pyramidal neurons. Despite signiﬁcant advances in under-
standing the molecular pathogenesis of SCA1, effective
treatments have not yet been revealed. The present study
suggests that lithium might safely improve the motor
coordination and cognitive function of SCA1 patients,
perhaps providing them with better quality of life. Trans-
lating successful drug trials in mouse models into a clinical
context is not always an easy task [43], but the fact that
lithium has been efﬁcacious in treating other human diseases
raises hope that it may be useful for therapeutic trials in
SCA1 patients, irrespective of its mechanism of action.
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Lithium Benefits SCA1 Mouse ModelEditors’ Summary
Background. Spinocerebellar ataxia type 1 (SCA1) is an inherited,
incurable neurodegenerative disease in which the neurons (cells that
transmit information between the brain and body) in the cerebellum (the
brain region that coordinates movement) gradually die. Symptoms of the
disease, which usually begins in early adult life, include poor
coordination of movement (ataxia), slurred speech, and cognitive
(learning and memory) problems. As more neurons die, these symptoms
get worse until breathing difficulties eventually cause death. SCA1 is a
‘‘triplet repeat disease.’’ Information for making proteins is stored in DNA
as groups of three nucleotides (codons), each specifying a different
amino acid (the building blocks of proteins). In triplet repeat diseases,
patients inherit a mutant gene containing abnormally long stretches of
repeated codons. In SCA1, the repeated codon is CAG, which specifies
glutamine. Consequently, SCA1 is a ‘‘polyglutamine disease,’’ a group of
neurodegenerative disorders in which an abnormal protein (a different
one for each disease) containing a long stretch of glutamine forms
nuclear inclusions (insoluble lumps of protein) in neurons that, possibly
by trapping essential proteins, cause neuronal death. In SCA1, the
abnormal protein is ataxin 1, which is made in many neurons including
the cerebellar neurons (Purkinje cells) that coordinate movement.
Why Was This Study Done? Early in SCA1, the production of several
messenger RNAs (the templates for protein production) decreases,
possibly because transcription factors (proteins that control gene
expression) interact with the mutant protein. Could the progression of
SCA1 be slowed, therefore, by using an agent that affects gene
expression? In this study, the researchers have investigated whether
lithium can slow disease progression in an animal model of SCA1. They
chose lithium for their study because this drug (best known for
stabilizing mood in people with bipolar [manic] depression) affects gene
expression, is neuroprotective, and has beneficial effects in animal
models of Huntington disease, another polyglutamine disease.
What Did the Researchers Do and Find? The researchers bred mice
carrying one mutant gene for ataxin 1 containing a very long CAG repeat
and one normal gene (Sca1
154Q/2Q mice; genes come in pairs). These mice
develop symptoms similar to those seen in people with SCA1. After
weaning, the mice and their normal littermates were fed normal food or
food supplemented with lithium for several weeks before assessing their
ability to coordinate their movements and testing their cognitive skills.
Dietary lithium (given before or after symptoms appeared) improved
both coordination and learning and memory in the Sca1
154Q/2Q mice but
had little effect in the normal mice. Lithium did not change the overall
appearance of the cerebellum in the Sca1
154Q/2Q mice nor reduce the
occurrence of nuclear inclusions, but it did partly reverse hippocampal
neuron degeneration in these animals. The researchers discovered this
effect by examining the shape of the hippocampal neurons in detail.
These neurons normally have extensive dendrites—branch-like projec-
tions that make contact with other cells—but these gradually disappear
in Sca1
154Q/2Q mice; lithium partly reversed this loss. Finally, lithium also
restored the level of Icmt/Pccmt mRNA in the cerebellum to near normal
in the Sca1
154Q/2Q mice—this mRNA is one of the first to be reduced by
ataxin 1 toxicity.
What Do These Findings Mean? These findings show that treatment
with lithium slows neurodegeneration in a mouse model of SCA1, even
when it is given only after the first symptoms of the disease have
appeared. Unfortunately, lithium did not improve the life span of the
Sca1
154Q/2Q mice (although this could be because the mutant SCA1
protein has some deleterious effects outside the brain). Thus, lithium is
unlikely to cure SCA1, but it could provide some help to people with this
devastating disease, even if (as is usual), their condition is not diagnosed
until the disease is quite advanced. However, because drugs that work in
animal models of diseases do not necessarily work in people, patients
with SCA1 (or other polyglutamine diseases, which might also benefit
from lithium supplementation) should not be treated with lithium until
human trials of this approach have been completed.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040182.
  The US National Ataxia Foundation provides information for patients
  International Network of Ataxia Friends has information for patients
and carergivers on ataxias, including SCA1
  GeneTests provides information for health care providers and
researchers about SCA1
  Online Mendelian Inheritance in Man (OMIM) has detailed scientific
information on SCA1
  Huntington’s Outreach Project for Education offers information for lay
people from Stanford University on trinucleotide repeat disorders
including SCA1
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